Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe

American Journal of Physiology - Endocrinology and Metabolism

Volumn 286, Issue 2 49-2, 2004, Pages

  Colca, Jerry R ^a   McDonald, William G ^a   Waldon, Daniel J ^a   Leone, Joseph W ^a   Lull, June M ^a   Bannow, Carol A ^a   Lund, Eric T ^a   Mathews, W Rodney ^a  

^a PFIZER INC   (United States)

Author keywords

Insulin sensitizers; mitoNEET; Novel site of action; Photoaffinity probes; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 [(3 CHOLAMIDOPROPYL)DIMETHYLAMMONIO] 1 PROPANESULFONIC ACID; CIGLITAZONE; MITOCHONDRIAL PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PNU 101074; PNU 91323; PNU 91325; PROTEIN MITONEET; ROSIGLITAZONE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN MITOCHONDRION; CATTLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG BINDING SITE; DRUG MECHANISM; GEL PERMEATION CHROMATOGRAPHY; LIVER MITOCHONDRION; MASS SPECTROMETRY; MITOCHONDRIAL MEMBRANE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHOTOAFFINITY LABELING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN ANALYSIS; PROTEIN CROSS LINKING; RAT; SKELETAL MUSCLE; WESTERN BLOTTING;

EID: 0942276510     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00424.2003     Document Type: Article

References (52)

1. Bailey CJ and Day C. Thiazolidinediones today. Br J Diab Vasc Dis 1: 7-13, 2001.
2. Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R, and Martin J. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. J Clin Ther 24: 378-396, 2002.
3. Brunmair B, Gras F, Neschen S, Roden M, Wagner L, Waldhausl W, and Fuernsinn C. Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-[gamma]-mediated changes in gene expression. Diabetes 50: 2309-2315, 2001.
4. Burant CF, Sreenan S, Hirano KI, Tai TAC, Lohmiller J, Lukens J, Davidson NO, Ross S, and Graves RA. Troglitazone action is independent of adipose tissue. J Clin Invest 100: 2900-2908, 1997.
5. Chakrabarti R, Vikramadithyan RK, Dileepkumar T, Kumar KB, Kumar MP, Misra P, Rao PB, Lohray BB, and Rajagopalan R. Studies on the euglycemic and hypolipidemic potentials of the novel indole analogue of thiazolidinedione, DRF 2189. Arzneimittel-Forschung 49: 905-911, 1999.
6. Chang AY, Wyse BM, Gilchrist BJ, Peterson T, and Diani AR. Ciglitizone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats. Diabetes 32: 830-838. 1983.
7. Chavez JA, Knotts TA, Wang LP, Li G, Dobrowsky RT, Florant GL, and Summers SA. A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J Biol Chem 278: 10297-10303, 2003.
8. Colca JR, Dailey CF, Palazuk BJ, Hillman RM, Dinh DM, Melchior GW, and Spilman CH. Pioglitazone hydrochloride inhibits cholesterol aborption and lowers plasma cholesterol concentrations in cholesterol-fed rats secondary to improved insulin sensitivity. Diabetes 40: 1669-1674, 1991.
9. Colca JR, McDonald WG, Waldon DJ, Thomasco LM, Gadwood RG, Lund ET, Cavey GS, Mathews WR, Adams LD, Cecil ET, Pearson JD, Bock JH, Mott JE, Shinabarger DL, Xiong L, and Mankin AS. Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J Biol Chem 278: 21972-21979, 2003.
10. Cooney GJ, Thompson AL, Furler SM, Ye J, and Kraegen EW. Muscle long-chain acyl CoA esters and insulin resistance. Ann NY Acad Sci 967: 196-207, 2002.
11. Eaton S, Bursby T, Middleton B, Pourfarzam M, Mills K, Johnson AW, and Bartlett K. The mitochondrial trifunctional protein: center of a β-oxidation metabolon? Biochem Soc Trans 28: 177-182, 2000.
12. Fleischer S and Fleischer B. Removal and binding of polar lipids in mitochondria and other membrane systems. In: Methods in Enzymology, edited by Estabrook RW and Pullman ME. New York: Academic, vol. X, 1967, p. 406-433.
13. Fuernsinn C and Waldhaeusl W. Thiazolidinediones: metabolic actions in vitro. Diabetologia 45: 1211-1223, 2002.
14. Fujita T, Sugiyama Y, Taketomi S, Sohda T, Kawamatsu Y, Iwatsuka H, and Suzuoki Z. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63287, Ciglitazone), a new antidiabetic agent. Diabetes 32: 804-810, 1983.
15. Gegick CG and Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr Pract 7: 162-169, 2001. (Erratum: Endocr Pract 7: July-August 2001, p. 330)
16. Gegick CG and Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr Pract 7: 162-169, 2001. (Erratum: Endocr Pract 7: July-August 2001, p. 330)
17. Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, and Lazar MA. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 8: 1122-1128, 2002.
18. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, Hagura R, Akanuma Y, Kimura S, Ito C, and Kadowaki T. The Pro12Ala polymorphism in PPAR 2 may confer resistance to type 2 diabetes, Biochem Bipohys Res Commun 271: 212-216, 2000.
19. Harris PK and Kletzien RF. Localization of a pioglitazone response element in the adipocyte fatty acid-binding protein gene. Mol Pharmacol 45: 439-445, 1994.
20. Hasstedt SJ, Ren QF, Teng K, and Elbein SC. Effect of the peroxisome proliferator-activated receptor-2 Prol2Ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds. J Clin Endocrinol Metab 86: 536-541, 2001.
21. Hiragun A, Sato M, and Mitsui H. Preadipocyte differentiation in vitro: identification of a highly active adipogenic agent. J Cell Physiol 13: 124-130, 1988.
22. Hofmann CA and Colca JR. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care 15: 1075-1078, 1992.
23. Ikeda H, Taketomi S, Sugiyama Y, Shimura Y, Sohda T, and Meguro K. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittel-Forschung 40: 156-162, 1990.
24. Ikonen E, Fiedler K, Parton RG, and Simons K. Prohibitin, an anti-proliferative protein, is localized to mitochondria. FEBS Lett 358: 273-277, 1995.
25. Khan MA, St. Peter JV, and Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 25: 708-711, 2002.
26. Kim JH, Lewin TM, and Coleman RA. Expression and characterization of recombinant rat acyl-CoA synthetases 1, 4, and 5. Selective inhibition by triacsin C and thiazolidinediones. J Biol Chem 276: 24667-24673, 2001.
27. Kletzien RF, Clarke SD, and Ulrich RG. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 41: 393-398, 1992.
28. Kletzien RF, Foellmi LA, Harris PK, Wyse BM, and Clarke SD. Adipocyte fatty acid-binding protein: regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent. Mol Pharmacol. 42: 558-562, 1992.
29. Komers R and Vrana A. Thiazolidinediones-tools for the research of metabolic syndrome X. Physiol Res 47: 215-225, 1998.
30. LaCivita KA and Villarreal G. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone. Curr Med Res Opin 18: 363-370, 2002.
31. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, and Kliewer SA. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272: 3406-3410, 1997.
32. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, and Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor [gamma] (PPAR [gamma]). J Biol Chem 270: 12953-12956, 1995.
33. Lowell BB. An essential regulator of adipogenesis and modulator of fat cell function. Cell 99: 239-242, 1999.
34. Miles PD, Barak Y, He W, Evans RM, and Olefsky JM. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest 105: 287-292, 2000.
35. Olefsky JM and Saltiel AR. PPAR gamma and the treatment of insulin resistance. Trends Endocrinol Metab 11: 362-368, 2000.
36. Owens DR. Thiazolidinediones: a pharmacological overview. Clin Drug Invest 22: 485-505, 2002.
37. Rami HK and Smith SA. Synthetic ligands for PPAR-γ-review of patent literature 1994-1999. Exp Opin Ther Patents 10: 623-634, 2000.
38. Reginato MJ, Bailey ST, Krakow SL, Minami CO, Ishii S, Tanaka H, and Lazar MA. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor-activating properties. J Biol Chem 273: 32679-32684, 1998.
39. Ruderman NB, Saha AK, Vavvas D, and Witters LA. Malonyl-CoA, fuel sensing, and insulin resistance. Am J Physiol Endocrinol Metab 276: E1-E18, 1999.
40. Saha AK, Kurowski TG, Colca JR, and Ruderman NB. Lipid abnormalities in tissues of the KKAy mouse: effects of pioglitazone on malonyl-CoA and diacylglycerol. Am J Physiol Endocrinol Metab 267: E95-E101, 1994.
41. Saltiel AR and Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45: 1661-1669, 1996.
42. Sizer KM, Smith CL, Jacob CS, Swanson ML, and Bleasdale JE. Pioglitazone promotes insulin-induced activation of phosphoinositide 3-kinase in 3T3-L1 adipocytes by inhibiting a negative control mechanism. Mol Cell Endocrinol 102: 119-129, 1994.
43. Sorbera LA, Castaner J, Del Fresno M, and Silvestre J. Netoglitazone. In: Drugs of the Future 27: 132-139, 2002.
44. Spiegelman BM. PPAR-[gamma]: adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507-514, 1998.
45. Stumvoll M and Haring H. The peroxisome proliferator-activated receptor γ2-Pro12Ala polymorphism. Diabetes 51: 2341-2347, 2002.
46. Tanis SP, Parker TT, Colca JR, Fisher RM, and Kletzien RF. Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone. J Med Chem 39: 5053-5063, 1996.
47. Uppenberg J, Svensson C, Jaki M, Bertilsson G, Jendeberg L, and Berkenstam A. Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma. J Biol Chem 273: 31108-31112, 1998.
48. Wagstaff AJ and Goa KL. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 62: 1805-1837, 2002.
49. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, and Lehmann JM. The structure-activity relationship between peroxisome proliferator-activated receptor [gamma] agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39: 665-668, 1996.
50. Ye JM, Frangioudakis G, Iglesias MA, Furler SM, Ellis B, Dzamko N, Cooney GJ, and Kraegen EW. Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver. Endocrinology 143: 4527-4535, 2002.
51. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, and Kim JK, Cushman SW, Cooney GJ, Atcheson B, White MF, Kraegen EW, and Shulman GI. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 277: 50230-50236, 2002.
52. Zierath JR, Ryder JW, Doebber T, Woods J, Wu M, Ventre J, Li Z, McCrary C, Berger J, Zhang B, and Moller DE. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPAR agonist) action. Endocrinology 139: 5034-5041, 1998.